Squarepoint’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-47,884
Closed -$724K 3756
2022
Q3
$724K Sell
47,884
-16,035
-25% -$186K ﹤0.01% 1977
2022
Q2
$479K Buy
63,919
+49,400
+340% +$348K ﹤0.01% 2034
2022
Q1
$132K Sell
14,519
-65,188
-82% -$502K ﹤0.01% 2563
2021
Q4
$560K Buy
79,707
+62,732
+370% +$656K ﹤0.01% 2068
2021
Q3
$194K Sell
16,975
-30,212
-64% -$442K ﹤0.01% 2502
2021
Q2
$755K Buy
+47,187
New +$809K ﹤0.01% 1838
2021
Q1
Sell
-51,417
Closed -$695K 3798
2020
Q4
$695K Buy
51,417
+16,260
+46% +$196K 0.01% 1573
2020
Q3
$414K Buy
35,157
+16,340
+87% +$199K 0.01% 1572
2020
Q2
$278K Buy
18,817
+1,751
+10% +$25.9K ﹤0.01% 1645
2020
Q1
$230K Sell
17,066
-64,339
-79% -$1.22M 0.01% 1411
2019
Q4
$1.97M Sell
81,405
-84,466
-51% -$1.75M 0.01% 914
2019
Q3
$3.19M Buy
165,871
+135,716
+450% +$3.11M 0.03% 636
2019
Q2
$891K Sell
30,155
-59,894
-67% -$2.31M 0.01% 1327
2019
Q1
$4.28M Buy
90,049
+79,372
+743% +$3.49M 0.05% 497
2018
Q4
$385K Sell
10,677
-17,263
-62% -$810K ﹤0.01% 1388
2018
Q3
$1.72M Buy
+27,940
New +$1.8M 0.02% 776
2018
Q2
Sell
-10,502
Closed -$570K 2150
2018
Q1
$570K Buy
+10,502
New +$587K 0.01% 1041
2017
Q3
Sell
-11,700
Closed -$615K 1967
2017
Q2
$615K Sell
11,700
-1,134
-9% -$52.8K 0.01% 885
2017
Q1
$582K Sell
12,834
-16,310
-56% -$727K 0.02% 800
2016
Q4
$1.1M Buy
29,144
+14,101
+94% +$533K 0.05% 470
2016
Q3
$568K Buy
+15,043
New +$332K 0.04% 517

Squarepoint's AERI Position: Q4 2022 in Review

Squarepoint sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 47,884 shares — an estimated $724K sold.

Squarepoint first reported a position in AERI in Q3 2016 and held it in 21 quarters. The position peaked at $4.28M in Q1 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Squarepoint reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Squarepoint sold 47,884 Aerie Pharmaceuticals shares in Q4 2022, an estimated $724K.
  • Squarepoint first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 21 quarters.
  • Squarepoint's Aerie Pharmaceuticals position peaked at $4.28M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Squarepoint's 13F filing for Q4 2022, filed 14 Feb 2023.